Trial Profile
A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Zimberelimab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 10 Jun 2021 Status changed from recruiting to completed.
- 09 May 2018 According to an Arcus Biosciences media release, dosing initiated in a third cohort and company expect to present safety, pharmacokinetic, receptor occupancy and clinical activity data in the second half of 2018.
- 20 Nov 2017 New trial record